Eiger BioPharmaceuticals, Inc.

Japanese gene therapy venture AnGes, Inc. has decided to withdraw an application for the full approval in Japan of its hepatocyte growth factor (HGF) gene therapy Collategene (beperminogene perplasm

Amylyx Pharmaceuticals, Inc. is rebuilding after a major setback earlier this year when its sole commercial drug, Relyvrio (sodium phenylbutyrate/taurursodiol) for amyotrophic lateral sclerosis (ALS)

Japanese gene therapy venture AnGes, Inc. has decided to withdraw an application for the full approval in Japan of its hepatocyte growth factor (HGF) gene therapy Collategene (beperminogene perplasm

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly The Latest Pharma Company To Sign